Optimal use of glucose polymer (icodextrin) in peritoneal dialysis.
The osmotic effectiveness of glucose polymer is now well established. The relative inertness of this macromolecular compound has been the key factor in its success as the first "colloid" osmotic agent in clinical use. In its present form, it produces sustained ultrafiltration for up to 12 hours, and a daily overnight use would obviate the need for hypertonic exchanges, especially 3.86% glucose. In addition, it could be used in automated peritoneal dialysis regimes to enhance ultrafiltration and solute clearance during the daytime. Preliminary reports also indicate that it is beneficial in diabetic patients and in some patients who have lost ultrafiltration. The new "bimodal" formulations look promising, with the potential to replace all the currently used hyperosmolar exchanges with physiological solutions. Although systemic accumulation of glucose polymer breakdown products occurs, it reaches steady-state levels quickly (within two weeks) and remains stable throughout the duration of polymer use. In the long-term study, these levels of maltose and oligosaccharides over three-and-a-half years represent the longest exposure of these substances in uremic patients without any clinical or metabolic adverse effects and provide an important evidence of safety. Future work based on studies that are ongoing suggest that a family of physiological solutions ("bimodal" preparations in iso-osmolar combination) could be available, and the individual's dialysis prescription could be tailored to take into account the ultrafiltration, metabolic needs, as well as the long-term viability of the membrane. Glucose polymer will be a key component of such solutions.
Mistry
C D
CD
Peterborough District Hospital, U.K.
Gokal
R
R
D003912:Dextrins / Q000493:pharmacokinetics; D015314:Dialysis Solutions / Q000493:pharmacokinetics*; D005936:Glucans / Q000493:pharmacokinetics*; D005950:Glucose Solution, Hypertonic / Q000493:pharmacokinetics; D006801:Humans; D007676:Kidney Failure, Chronic / Q000503:physiopathology* / Q000628:therapy; D008320:Maltose / Q000493:pharmacokinetics; D009995:Osmosis; D010530:Peritoneal Dialysis; D010531:Peritoneal Dialysis, Continuous Ambulatory; D017211:Treatment Failure; D014462:Ultrafiltration; D014882:Water-Electrolyte Balance / Q000502:physiology*
D003912:Dextrins; D015314:Dialysis Solutions; D005936:Glucans; D005950:Glucose Solution, Hypertonic; D008320:Maltose